CellPrime rAlbumin AF-G was developed in response to increasing demand for cell culture supplements that contain no human or animal ingredients in order to ease regulatory concerns for biopharmaceutical manufacturers. CellPrime rAlbumin AF-G offers multiple benefits including the maintenance of osmotic balance and transport, the distribution of fatty acids and amino acids, as well as improving consistency of customers’ industrial cell culture processes.

"A critical part of Millipore’s long-term strategy is to expand our portfolio of animal-free cell culture supplements we can offer to our customers,” said Andrew Bulpin, Vice President of Millipore’s Upstream Bioprocessing Business Unit. “CellPrime rAlbumin AF-G meets the unique challenges of industrial cell culture by providing a defined, animal-free albumin, which enables customers to take advantage of the benefits of albumin without the challenges associated with animal or human derived supplements."

CellPrime rAlbumin AF-G is the third product to be launched in the animal-free CellPrime range and further strengthens the existing partnership between Novozymes and Millipore. Building on Millipore Corporation’s and Novozymes Biopharma’s strong positions in the biopharmaceutical market, this new product will be manufactured by Novozymes

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide. For more information, visit www.millipore.com.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries Novozymes creates tomorrow’s industrial biosolutions, improving the customers' business and the use of the planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations increase industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.

Millipore Forward Looking Statement
The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results with respect to the foregoing include, without limitation, failure to achieve market penetration or to develop additional products acceptable to the cell culture market, failure to achieve design wins into our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug; delay, suspension or termination of a customer's volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; the inability to realize the expected benefits of the Novozymes development, marketing and licensing alliance; competitive factors such as alternative cell culture supplements; the inability to utilize technology in current or planned products due to overriding rights by third parties; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; and exposure to product liability claims. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

ADVANCING LIFE SCIENCE TOGETHER^TM
Research. Development. Production.

Millipore Contacts
Millipore Media Contact:
Karen Marinella Hall
Director of Corporate Communications
(978) 715 -1567
karen_hall@millipore.com

Millipore Investors Contact:
Joshua Young
Director, Investor Relations
(978) 715 -1527
joshua_young@millipore.com

Novozymes Contact:
Sally Vernon, Marketing Communications Manager
+ 44 115 9551209
syke@novozymes.com